I-Omicron BA.2 subvariant ibonakala ngathi igqithisekile kune-BA.1. Ikwanazo neepropathi ezikhusela amajoni omzimba ezinciphisa ngakumbi isiphumo sokhuselo logonyo ngokuchasene nosulelo.
Nge-26 kaNovemba ka-2021, i-WHO yayichonge i-B.1.1.529 eyahlukileyo SARS-selwe-2 njengeNgcaciso yenkxalabo (VOC), kwaye inikwe igama Micron.
Njengamhla, i-Omicron iquka umgca wePango B.1.1.529 kunye nokwehla Pango imigca BA.1, BA.1.1, BA.2 kunye BA.3. Utshintsho oluchazayo lugqithelana ngokupheleleyo nomnombo we-BA.1. Uluhlu lwenzala ye-BA.2 luhluke kwi-BA.1 kwezinye iinguqu, kubandakanywa neprotheni ye-spike.
Ukwahluka kwe-BA.2 kuyanda kumazwe amaninzi. Kumazwe aliqela, amabini Micron subvariants ziqatshelwe BA.1 kunye BA.2.
E-Denmark, i-BA.2 ithathe indawo ye-BA.1 ngokukhawuleza kwaye ibe yi-subvariant elawulayo. Kuhlolisiso olutshanje lwelizwe lonke lwamakhaya aseDenmark, izinga lokuhlaselwa kwesibini (SAR) liqikelelwa njenge-29% kunye ne-39% kumakhaya anesifo se-Omicron BA.1 kunye ne-BA.2, ngokulandelanayo.
I-BA.2 yafunyaniswa inxulumene nokunyuka kokungenwa kwentsholongwane kubantu abangagonywanga (i-Odds Ratio 2.19), abantu abagonywe ngokupheleleyo (OKANYE 2.45) kunye nabantu abagonywe nge-booster-vaccinated (OKANYE 2.99), xa kuthelekiswa ne-BA.1.
Abaphandi baye bafumana ukwanda Ukudluliselwa ukusuka kumatyala aphantsi angagonywanga kwi-BA.2 kumakhaya xa kuthelekiswa ne-BA.1 kumakhaya. Ipatheni yokunyuka kokusuleleka kwimizi ye-BA.2 ayizange iqwalaselwe kugonyo olupheleleyo kunye ne-booster-vaccination primary cases.
Ukuququmbela, Micron I-BA.2 subvariant ibonakala ngathi yosulela ngakumbi kune-BA.1. Ikwanazo neepropathi ezikhusela amajoni omzimba ezinciphisa ngakumbi isiphumo sokhuselo logonyo ngokuchasene nosulelo.
***
Imithombo:
- WHO 2022. Ukulandelela ukwahluka kwe-SARS-CoV-2. Ifumaneka e https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ Ifikeleleke nge-04 kaFebruwari 2022.
- Lyngse FP, okqhubekayo 2022. Ukuhanjiswa kweSARS-CoV-2 Omicron VOC subvariants BA.1 kunye BA.2: Ubungqina obuvela kuMakhaya aseDanish. Shicilela kwangaphambili medRxiv. Ithunyelwe nge-30 kaJanuwari 2022. DOI: https://doi.org/10.1101/2022.01.28.22270044
***
